Nano-scale coatings and related methods suitable for in-vivo use
10722696 ยท 2020-07-28
Assignee
Inventors
Cpc classification
B82Y5/00
PERFORMING OPERATIONS; TRANSPORTING
A61M2205/0238
HUMAN NECESSITIES
A61M2205/025
HUMAN NECESSITIES
B01L3/502707
PERFORMING OPERATIONS; TRANSPORTING
A61L2400/12
HUMAN NECESSITIES
A61M2207/00
HUMAN NECESSITIES
A61L27/306
HUMAN NECESSITIES
International classification
A61M31/00
HUMAN NECESSITIES
Abstract
A nano-scale device and method of manufacturing and use. The nano-scale device may be used in-vivo and may comprise a fluid path with an inlet microchannel, an outlet microchannel, and a nanochannel. The fluid path comprises a bio-robust material. In certain embodiments, the bio-robust material may be coated over a material that is not bio-robust.
Claims
1. A nanochannel delivery device comprising: an inlet microchannel comprising a first sidewall; an outlet microchannel comprising a second sidewall; and a nanochannel etched between a first bio-robust layer and a second bio-robust layer, wherein: the first bio-robust layer is a silicon carbide layer; the second bio-robust layer is a silicon carbide layer; the etched nanochannel is in fluid communication with the inlet microchannel and the outlet microchannel; the inlet microchannel comprises a first bio-robust coating on the first sidewall of the inlet microchannel, wherein the first bio-robust coating is a tantalum oxide coating; the outlet microchannel comprises a second bio-robust coating on the second sidewall of the outlet microchannel, wherein the second bio-robust coating is a silicon carbide coating; and the first bio-robust coating is atomically sealed to the first bio-robust layer; and the second bio-robust coating is atomically sealed to the second bio-robust layer.
2. The nanochannel delivery device of claim 1 wherein the inlet microchannel comprises the first bio-robust coating atomically sealed to a non-bio-robust material.
3. The nanochannel delivery device of claim 1 wherein the outlet microchannel comprises the second bio-robust coating atomically sealed to a non-bio-robust material.
4. The nanochannel delivery device of claim 1 wherein: the first bio-robust coating is atomically sealed to the second bio-robust layer; and the second bio-robust coating is atomically sealed to the first bio-robust layer.
5. The nanochannel delivery device of claim 1 wherein the nanochannel is in direct fluid communication with the inlet microchannel and the outlet microchannel.
6. The nanochannel delivery device of claim 1 wherein the height of the etched nanochannel is less than 200 nm.
Description
BRIEF DESCRIPTION OF THE FIGURES
(1)
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
(2) As previously mentioned, in certain applications a nanochannel delivery device may be implanted into a human or animal body. It is therefore desirable that the materials exposed to bio-fluids be resistant to attack from those fluids. In certain applications, materials used in the construction of an NDD may not be resistant to bio-fluids.
(3) For example, bio-fluids may cause corrosion or erosion of silicon, silicon dioxide and silicon nitride. The NDD embodiments disclosed in the '233 and '937 Applications incorporate silicon nitride and silicon as the ceiling and floor of the nanochannels. While silicon nitride provides good tensile strength, it does not generally exhibit good corrosion/erosion resistance in certain applications in the human body (11,12)
(4) Therefore, it can be desirable to provide a coating of material that is bio-robust over a material that provides beneficial mechanical strength. As used herein, bio-robust materials include materials configured to withstand bio-fluids at body temperature (e.g., approximately 37 degrees Celsius) or elevated temperatures for extended periods of time. In specific embodiments, bio-robust materials maintain nanometer scale dimensions within 10 percent of their original dimensions over 1,000 days when exposed body fluids or equivalent at body temperature. These materials may include, for example, silicon carbide (SiC), tantalum oxide (Ta.sub.2O.sub.5), and other materials. Such materials may be deposited by chemical vapor deposition (CVD), atomic layer deposition (ALD), sputtering or by spin-on deposition, or a combination of these methods. In the exemplary embodiment described below, tantalum oxide is used to provide a bio-robust material in the inlet microchannels, while silicon carbide or Tantalum oxide/silicon carbide bilayer is used to provide a bio-robust material in other areas of the NDD that could be exposed to bio-fluids.
(5) Embodiments of the present disclosure do not require that the structural material of the NDD be both bio-robust and structurally adequate. Instead, materials that are not bio-robust, but structurally sound (e.g., possessing the required tensile, compressive, and/or shear strengths) can be coated or covered with bio-robust materials. The bio-protection of this structural material (with the weak bio-robustness) comes from the application of a second layer which is used as a lining, whose primary purpose is to provide bio-robustness. This lining layer material can then have a relaxed requirement of structural adequacy. This allows for use of a material with limited strength/stress but adequate bio-robustness with a material with limited bio-robustness, but with adequate strength/stress.
(6) Exemplary embodiments use a sacrificial channel material that can be selectively removed after the full device fabrication to create a nanochannel. Any material that can be wet-etched with a high selectivity with respect to other materials in the system can be used as the nanochannel material. The exemplary embodiment described below is based on Protocol 3 (Monolithically-Fabricated Capping Layer) disclosed in the '233 and '937 Applications.
(7) Referring initially to
(8) Referring now to
(9) As shown in
(10) If the bio-robust material is incapable of resisting further process materials or conditions, additional sacrificial layers 114 and 116 can be deposited as shown in
(11) As shown in
(12) The structure may then be filled with a material 121 with a high conformality, as shown in
(13) As shown in
(14) Referring now to
(15) As shown in
(16) Referring now to
(17) As shown in
(18) As shown in
(19) At this stage, wafer 100 can turned over, as shown in
(20) Referring to
(21) Macrochannels are then etched in layer 103, stopping at oxide layer 105, as shown in
(22) The wafer is then flipped over to face-up position, as shown in
(23) While one exemplary embodiment has been described above, other exemplary embodiments may comprise alternate processes or methods. For example, the processes described in
(24) Furthermore, the process described in
(25) An alternate method to make the devices with materials protected by bio-robust layers is by changing the sequence of line and inlet formation process from line first, inlet second, to inlet first and line second. This can be accomplished, for example, in the manner described below.
(26)
(27) Referring now to
(28) Referring now to
(29) In exemplary embodiments, it can be desirable to provide sealing of bio-robust materials so that the non-bio-robust materials are not exposed to bio-fluids. In specific embodiments, the bio-robust materials atomically seal to the non-bio-robust material that needs to be protected (without gaps for the bio-fluids to get through). In addition, the bio-robust layers seal to each other (e.g. sidewalls and top layers of channels). The bio-robust layer may also serve to adhere adjacent layers.
(30) In particular embodiments, atomic layer deposition (ALD) may be used because the layers are extremely conformal to residual surface topography in underlying layers. Examples of materials suitable for ALD include, but are not limited, to: Al.sub.2O.sub.3, Ta.sub.2O.sub.5, HfO.sub.2, HfSiO.sub.2, ZrO.sub.2, AlSiO.sub.2, TiN, Ti, TiAlN, AlN, HfN, TaN, TaCN, HfSiN, TiO. A table of additional materials that may be used for ALD is provided below.
(31) TABLE-US-00001 Compound class Examples II-VI compounds ZnS, ZnSe, ZnTe, ZnS.sub.1xSe.sub.x, CaS, SrS, BaS, SrS.sub.1xSe.sub.x, CdS, CdTe, MnTe, HgTe, Hg.sub.1xCd.sub.xTe, Cd.sub.1xMn.sub.xTe II-VI based thin-film ZnS:M (M = Mn, Tb, Tm), CaS:M electroluminescent (TFEL) (M = Eu, Ce, Tb, Pb), phosphors SrS:M (M = Ce, Tb, Pb, Mn, Cu) III-V compounds GaAs, AlAs, AlP, InP, GaP, InAs, Al.sub.xGa.sub.1xAs, Ga.sub.xIn.sub.1xAs, Ga.sub.xIn.sub.1xP Semiconductors/dielectric AlN, GaN, InN, SiN.sub.x nitrides Metallic nitrides TiN, TaN, Ta.sub.3N.sub.5, NbN, MoN Dielectric oxides Al.sub.2O.sub.3, TiO.sub.2, ZrO.sub.2, HfO.sub.2, Ta.sub.2O.sub.5, Nb.sub.2O.sub.5, Y.sub.2O.sub.3, MgO,CeO.sub.2, SiO.sub.2, La.sub.2O.sub.3, SrTiO.sub.3, BaTiO.sub.3 Transparent conductor oxides In.sub.2O.sub.3, In.sub.2O.sub.3:Sn, In.sub.2O.sub.3:F, In.sub.2O.sub.3:Zr, SnO.sub.2, SnO.sub.2:Sb, ZnO, Semiconductor oxides ZnO:Al, Ga.sub.2O.sub.3, MO, CoO.sub.x Superconductor oxides YBa.sub.2Cu.sub.3O.sub.7x Fluorides CaF.sub.2, SrF.sub.2, ZnF.sub.2
(32) Bio-robust materials may be deposited using only ALD, only CVD, or a combination of ALD and CVD. Additionally, the ALD and CVD materials can be deposited by thermally activated as well as by plasma or UV activated processes. In certain embodiments, the ALD layer can be a single layer or a multi-layer. In case of multi layers, one or more of these can be sacrificial liners that are etched away during the processing of the device leaving behind an underlayer that can still be protective in nature.
(33) Additionally, bio-robust materials may be deposited by sublimation, as in the case of Parylene in its various forms.
(34) While silicon nitride has been provided as an example of one non-bio-robust material, other materials include metals such as tungsten, copper, titanium, gold, platinum, ruthenium, aluminum, silver and other, as well as dielectrics. A partial list of dielectrics includes silicon and compounds of silicon such as oxides, nitrides, carbides, oxy nitrides, carbo-nitrides and oxy-carbides. Methyl silsequioxanes, hydrogen silsequioxanes and other organic silicates can be appropriately used. In addition plastics and polymeric materials such as PolyMethylMethAcrylate (PMMA), PolyCarbonate, PolyPropylene, Teflon and SU-8 can be used.
(35) All of the devices, systems and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the devices, systems and methods of this invention have been described in terms of particular embodiments, it will be apparent to those of skill in the art that variations may be applied to the devices, systems and/or methods in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
REFERENCES
(36) The contents of the following references are incorporated by reference herein: [1] Santen, R. J., Yue, W., Naftolin, F., Mor, G., Berstein, L. The potential of aromatase inhibitors in breast cancer prevention. Endocrine-Related Cancer. 6, 235-243 (1999). [2] Goss, P. E., Strasser, K. Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer. J. Clin. Oncol. 19, 881-894 (2001). [3] Chlebowski, R. T. Reducing the Risk of Breast Cancer. N. Engl. J. Med., 343, 191-198 (2000). [4] Dowsett, M., Jones, A., Johnston, S. R., Jacobs, S., Trunet, P., Smith, I. E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res. 1, 1511-1515 (1995). [5] Brueggemeier, R. W., Hackett, J. C., Diaz-Cruz, E. S. Aromatase Inhibitors in the Treatment of Breast Cancer. Endocrine Reviews 26, 331-345 (2005). [6] Coates, A. S., Keshaviah, A., Thrlimann, B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007). [7] Goss, P. E., Ingle, J. N., Martino, S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003). [8] Garreau, J. R., Delamelena, T., Walts, D., Karamlou, K., Johnson, N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 192, 496-8 (2006). [9] Luthra, R., Kirma, N., Jones, J., Tekmal, R. R. Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice. The Journal of Steroid Biochemistry and Molecular Biology. 86, 461-467 (2003). [10] Harper-Wynne, C., Ross, G., Sacks, N., Salter, J., Nasiri, N., Iqbal, J., A'Hern, R., Dowsett, M. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol. Biomarkers Prev. 11,614-21 (2002). [11] J. Maloney, S. Lipka and S. Baldwin, In Vivo Biostability of CVD Silicon Oxide and Silicon Nitride Films, Mater. Res. Soc. Symp. Proc. Vol. 872 (2005) [12] H Hammerle, K. Kobuch, K. Kohler, W. Nisch, H. Sachs, M. Stelzle, Biomaterials, 23, p 797-804 (2002)